Organs, by design.
We grow scaffold-free tissue building blocks from cells alone, then assemble them bottom-up into multi-tissue bioassembloids. One platform for every organ, in vitro and in vivo. Our lead program is a one-time, permanent bioassembled pancreas for Type 1 Diabetes.
Millions of organs are needed every year. Complex ones remain out of reach.
Stem cell injections fail to regenerate damaged organs, and tissue-engineered products are limited to simple tissues like skin, bone and cartilage. The answer sits between too simple and too complex.
Anchored Cell Sheet Engineering
Cells grow on engineered surfaces, secrete and organize their own extracellular matrix, and are then guided by anchors to remodel into mature 3D building blocks. No scaffolds, bioinks or animal-derived matrices are added at any step.
No foreign body reaction, no degradation byproducts and no xenogeneic risk. Native cell–cell and cell–ECM interactions stay intact.
Anchors on nano- to micro-patterned flexible membranes set the shape, mechanics and dimensions of each construct. Release needs no temperature change or other trigger.
The same process works across cell types and tissues, and fits existing clinical workflows from standard expansion to implantation by standard surgery.
Every building block an organ needs.
Sheets, fibers, spheres, and hollow tubes and spheres with a preserved lumen. Each one forms in three to four weeks and is the most in vivo-like version of that form factor, because nothing in it came from outside the cells.
Snap the blocks together. Let the body finish the last mile.
Building blocks are assembled bottom-up, like LEGO, into multi-tissue bioassembloids. They carry enough structural and functional complexity for long-term stability, then integrate and complete regeneration in vivo.
to form a mature building block
to produce a complex organ such as a pancreas
exogenous biomaterial in any construct
granted US patent term, one of four patent families
Cell proliferation
Hyperflasks or bioreactors expand cells to the target requirement.
Cell culture
Gold-standard 2D differentiation inside Evolved's custom culture cassettes.
Biofabrication & bioassembly
Cell-guided self-assembly forms fully structured tissues, then multi-tissue constructs.
Implantation & regeneration
Standard surgery, no extra training, complete biological integration.
A bioassembled pancreas. One procedure, for good.
people live with T1D worldwide; prevalence is expected to double in 15 years
people with T1D in the United States
spent on T1D in the US every year
of life expectancy lost, even with insulin therapy
Native pancreasBioassembled
Ectopically implanted β-cell clusters have been tried again and again for three decades. We rebuild the organ's architecture instead, with the hardest parts already de-risked.
- Proven path from iPSCs to every cell type the organ needs.
- All major components already optimized in their proper form factors.
- Fully allogeneic, designed to work without immunosuppression.
- A permanent, one-time treatment instead of a lifetime of repeat therapy.
The same product can serve other high-value indications such as type 2 diabetes and obesity. Programs like this are eligible for FDA Fast Track and RMAT and EMA PRIME designation.
Validated in vivo. Benchmarked in vitro.
Most of our data so far is in skeletal muscle, the proving ground for the platform.
Muscle-specific acellular ECM fibers repair volumetric muscle loss
Our simplest product, in vitro-made and decellularized muscle ECM fibers, was tested in rat models of volumetric muscle loss against a commercial porcine ECM.
- Preserved muscle mass
- Controlled inflammation and fibrosis
- Promoted vascularization
- Supported new muscle fiber formation
Acta Biomaterialia · 2025 · open to partnering this program
Patient-derived 3D models of muscular dystrophy
Scaffold-free skeletal muscle tissues built from patient cells reproduce disease phenotypes and drug responses, giving pharma and academic labs models with high physiological and pathological relevance.
- Duchenne (DMD) and myotonic dystrophy type 1 (MD1) vs healthy control
- Co-developing a skeletal muscle modeling kit with industrial and academic partners
- In discussion with a cohort of pharma partners
Advanced Healthcare Materials · 2024 · journal cover 2025
Beyond organ regeneration.
The same building blocks deliver cells, produce tissue-specific secretomes and model disease. Near-term programs generate revenue while the pancreas advances.
Organ regeneration
Multi-tissue bioassembloids for skeletal muscle and pancreas, implanted by standard surgery.
Cell & gene therapy delivery
A delivery system with better engraftment and retention than injection.
Longevity products
Exosomes, EVs, mitochondria and ECM from mature 3D constructs: more tissue-specific content and steadier long-term output than 2D culture.
In vitro models
High-relevance tissue models and a skeletal muscle kit for drug discovery.
Built to become a tissue foundry.
Optimized on proteomic and imaging data
A multimodal model steers each process toward physiological relevance, speed and quality.
Closed-loop, stand-alone manufacturing
Proof of concept for an automated, closed-loop system that runs the whole process.
Four patent families
Including a granted US patent valid to 2042, covering the anchored platform.
A short path to the clinic
ACSE is a strong candidate for FDA Advanced Manufacturing Technology designation, and our lead indications are positioned for expedited pathways.
Founded by the people who built the platform.
Let's help hundreds of millions of people heal, for good.
Partner, invest or collaborate with us on the world's first tissue foundries for in vivo-like tissues.
info@itsevolved.comCopied
Angel investors
Elevate IP